Public Companies
Mydecine Attempts to Raise Money With New Prospectus
Psychedelics firm Mydecine Innovations Group Inc. (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), which is still in the pre-revenue stage, announced a plan to offer…
Psychedelics firm Mydecine Innovations Group Inc. (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), which is still in the pre-revenue stage, announced a plan to offer 18.75 million additional shares for distribution at 20 cents apiece, in an attempt to raise $3.75 million.
The offering, outlined in a prospectus filed with Canadian securities regulators late last week, the offering was expected to close over the weekend, according to a press release from Mydecine.
If successful, the money will be used first and foremost “to assist in the transition to the (Canadian Securities Exchange,” according to the prospectus, which could be considered an uplisting from the NEO exchange on which Mydecine now trades in Canada.
In addition, the money raised would also be used to “settle outstanding fees owed to the NEO (exchange), to fund and develop the company’s research and development initiatives, intellectual property portfolio, its clinical trials and research partnerships, its continued development and drug pipeline and for general working capital purposes,” according to the prospectus.
The new 18.75 million shares would join the existing 26.4 million shares of Mydecine already being traded.
The move is the latest in a lengthy string of capital raise moves made by Mydecine executives, and the company has also had something of a revolving door of c-suite leaders.
Mydecine is also essentially broke, and had only about C$10,000 in the bank as of May. ”MYCO_-_Prospectus_Supplement_(Equity_Financing)_[Filing_Version
”]
The post Mydecine Attempts to Raise Money With New Prospectus appeared first on Green Market Report.
psychedelics shares fund otc capital mydecine innovations group mydecine research-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Ketamine1 week ago
Clinical-Stage BioTech Drug Stocks Portfolio UP 7% In w/e May 3rd
-
Psychedelics1 week ago
Optimi Health Provides Corporate Update
-
Law & Regulation1 week ago
Horizons talk shifts from investors to insurance
-
Law & Regulation1 week ago
DEA psychedelics ban hearing halted by lawsuit
-
Law & Regulation6 days ago
Relmada loses another $21.8M, makes progress with clinical trials
-
Psychedelics5 days ago
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001